G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Mantle Cell Lymphoma Growth in Preclinical Models
Authors:
Open Access
- 15 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin’s B-cell lymphoma with poor prognosis. Despite recent advances, resistance to therapy and relapse remain significant clinical problems. G-protein-coupled estrogen receptor (GPER)-mediated estrogenic rapid signaling is implicated in the development of many cancers. However, its role in MCL is unknown. Here we report that GPER activation with selective agonist G-1 induced cell cycle arrest, DNA damage, mitochondria membrane potential abnormality, and eventually apoptosis of MCL cell lines. We found that G-1 induced DNA damage and apoptosis of MCL cells by promoting the expression of nicotinamide adenine dinucleotide phosphate oxidase and the generation of reactive oxygen species. In addition, G-1 inhibited MCL cell proliferation by inactivation of NF-κB signaling and exhibited anti-tumor functions in MCL xenografted mice. Most significantly, G-1 showed synergistic effect with ibrutinib making it a potential candidate for chemotherapy-free therapies against MCL.Keywords
This publication has 53 references indexed in Scilit:
- Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphomaBlood, 2018
- Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)British Journal of Haematology, 2018
- The potential for chemotherapy-free strategies in mantle cell lymphomaBlood, 2017
- Postibrutinib outcomes in patients with mantle cell lymphomaBlood, 2016
- Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomesAnnals of Oncology, 2015
- Mantle cell lymphoma: evolving management strategiesBlood, 2015
- Landscape of somatic mutations and clonal evolution in mantle cell lymphomaProceedings of the National Academy of Sciences, 2013
- Unbiased estimates of long‐term net survival of hematological malignancy patients detailed by major subtypes in FranceInternational Journal of Cancer, 2012
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraBlood, 2011
- Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profilingBlood, 2010